Clinical effects of dapagliflozin in patients with type 2 diabetes mellitus and paroxysmal atrial fibrillation


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background. The incidence of atrial fibrillation (AF) in type 2 diabetes mellitus (DM2) is approximately one third higher than in individuals without DM. The place of sodium-glucose co-transporter-2 inhibitors in patients with DM2 in combination with atrial fibrillation (AF) needs to be clarified. Objective. Evaluation of the effect of dapagliflozin compared with other hypoglycemic drugs on the frequency of AF episodes, left atrial (LA) size, and clinical and laboratory parameters in patients with DM2 and paroxysmal AF in a randomized, prospective, open-label study. Methods. 68 patients with DM2 and paroxysmal AF were followed-up. For the treatment of AF, a rhythm control strategy was chosen; approaches to cardioversion and subsequent treatment were in line with current domestic and international recommendations. After randomization, group A (37 patients) was selected for the use of the combination of metformin and dapagliflozin (10 mg/day) as hypoglycemic therapy, and group B (31 patients) - for the use of metformin in combination with sulfonylurea drugs. The follow-up period was 11.4 (5.9) months. Results. The treatment contributed to the effective achievement of target glycemic levels by all patients and was satisfactorily tolerated. Relapses of AF paroxysms during the follow-up period occurred in 8 (21.6%) patients in group A and in 15 (48.4%) patients in group B (P<0.05). During treatment in both groups, there was a significant decrease in the LA volume index, body mass index, functional class of chronic heart failure (CHF), microalbuminuria, glycated hemoglobin and blood pressure levels, as well as an increase in left ventricular ejection fraction; these favorable changes were more pronounced in group A than in group B (P<0.01). Conclusion. The use of dapagliflozin in patients with DM2 and paroxysmal AF was satisfactorily tolerated, contributed to a decrease in the size of the LA and a decrease in the frequency of arrhythmia relapses, and was also associated with achieving adequate glycemic control and improving the clinical picture of CHF.

全文:

受限制的访问

作者简介

A. Bagriy

M. Gorky Donetsk National Medical University

Donetsk, DPR

O. Prikolota

M. Gorky Donetsk National Medical University

Donetsk, DPR

Alina Prikolota

M. Gorky Donetsk National Medical University

Email: prikav@yandex.ru
Cand. Sci. (Med.), Teaching Assistant at the Department of Therapy, FIPO n.a. professor A.I. Dyadyk Donetsk, DPR

E. Mikhailichenko

M. Gorky Donetsk National Medical University

Donetsk, DPR

I. Golodnikov

M. Gorky Donetsk National Medical University

Donetsk, DPR

O. Bagriy

Donetsk Regional Clinical Territorial Medical Association

Donetsk, DPR

K. Kotova

M. Gorky Donetsk National Medical University

Donetsk, DPR

参考

  1. American Diabetes Association. Cardiovasculardisease and risk management: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(S1):S111-S134. doi: 10.2337/dc20-s010.
  2. Cosentino F, Aboyans V., Bailey C.J., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J.2020;41 (2):255-323. Doi: 10.1093/ eurheartj/ehz486.
  3. Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Сахарный диабет 2 типа у взрослых: клинические рекомендации. Сахарный диабет.2020;23(S2):4-102.
  4. Cosentino F, Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J.2019;00:1-69.
  5. Wang A., Green J.B., Halperin J.L., et al. Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. JAAC.2019;74(8):1107-15. doi: 10.1016/j.jacc.2019.07.020.
  6. Hindricks G., Potpara T, Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J.2020;42:373-498. doi: 10.1093/eurheartj/ehaa612.
  7. McMurray J.J.V, DeMets D.L., inzucchi S.E. et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019;21(5):665-75. Doi: 10.1002/ ejhf.1432.
  8. Solomon S.D., Jhund PS., Claggett B.L., et al. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril. Valsartan: The DAPA-HF Trial. JACC Heart Fail.2020;8(10):811-18. Doi: 10.1016/j. jchf.2020.04.008.
  9. Butt J.H., Docherty K.F, Jhund PS., et al. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail. 2022;24(3):513-25. doi: 10.1002/ejhf.2381.
  10. Newman J.D., Schwartzbard A.Z., Weintraub H.S., et al. Primary prevention of cardiovascular disease in diabetes mellitus. JACC. 2017;70(7):883-93. doi: 10.1016/j.jacc.2017.07.001.
  11. Zelniker T.A., Bonaca M.P, Furtado R.H.M., et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation. 2020;141:1227-34. Doi: 10.1161/ CiRCULATiONAHA.119.044183.
  12. Pathak R.K., Middeldorp M.E., Meredith M., et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: a Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol. 2015;65:2159-69. Doi: 10.1016/j. jacc.2015.03.002.
  13. Sjstrm C.D., Johansson P, Ptaszynska A., et al. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab. Vasc. Dis. Res.2015;12(5):352-58. doi: 10.1177/1479164115585298.
  14. List J.F, Woo V, Morales E., et al. Sodium-dependent cotransport inhibitor with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650-57. doi: 10.2337/dc08-1863.
  15. Arnett D.K., Blumenthal R.S., AlbertM.A. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology. American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:596-646. Doi: 10.1161/ CiR.0000000000000678.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2022